Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$19.62M-$19.62MN/M vs Q3 2023 EPS Diluted-$0.48-$0.48N/M vs Q3 2023 Operating Income-$3,089,000N/M Operating Cash Flowderived-$7,101,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,106,000N/M ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end